NEXT BIOTECH

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?

GTG Validates Cancer Tests As it Looks to Global Expansion

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Canada Legalises Cannabis as CPH Moves Front and Centre With a 100% Owned Canadian Growing Facility

This week, Canada has become the second country in the world — and the first industrialised nation — to legalise recreational cannabis use nationwide. ASX cannabis innovator, Creso Pharma (ASX:CPH), has welcomed this change with open arms.

ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment

Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.

CPH has a Thirst for Bringing its Branded Cannabis Lifestyle Products to the World

Creso Pharma (ASX:CPH) is one step closer to launching its range of cannabis infused products.

IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops

Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.

MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence

Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism

Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.

Revolutionary MedTech Device: a New Frontier in Autism Treatment

Today’s company has created the first and only regulated medical device for the management of autism in a home setting.

IMC Reports Rising Revenues & Eyes Colitis Market

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

PTX Breast Cancer Trial Results Exceed Industry Expectations

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.

Thanks for subscribing!

X